NCT06324695 (DEVISE) is a NA clinical trial of HautKompass in Psoriasis, sponsored by Universitätsklinikum Hamburg-Eppendorf.

Who is sponsoring NCT06324695?

NCT06324695 is sponsored by Universitätsklinikum Hamburg-Eppendorf.

What drugs are being tested in NCT06324695?

Interventions in NCT06324695: HautKompass.

What condition does NCT06324695 study?

NCT06324695 studies Psoriasis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Atopic Dermatitis.

Is NCT06324695 still recruiting?

NCT06324695 is currently completed. Last updated 8 June 2025.

Last reviewed 2025-06-08 · How we verify

NCT06324695: DEVISE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases

Completed NA Last updated 8 June 2025

What this trial tests

NA trial testing HautKompass in Psoriasis in 298 participants. Completed in 27 May 2025.

Timeline

1 March 2024

Primary endpoint
13 December 2024

27 May 2025

Quick facts

Lead sponsor	Universitätsklinikum Hamburg-Eppendorf
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	298
Start date	1 March 2024
Primary completion	13 December 2024
Estimated completion	27 May 2025
Sites	12 locations across Germany

Drugs / interventions tested

HautKompass

Conditions studied

Psoriasis — all drugs for Psoriasis →
Alopecia Areata — all drugs for Alopecia Areata →
Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →
Vitiligo — all drugs for Vitiligo →

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

18 and older, any sex, with Psoriasis or Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to develop and evaluate an online intervention to prevent and/or reduce self-stigma in German patients with visible chronic skin diseases. Evaluation of the intervention with regard to effectiveness and feasibility will follow an open-label randomized controlled design with 550 patients in total. The results of the program are expected to provide new insights and markedly extended knowledge on the mechanisms of self-stigma in chronic skin conditions. The new online intervention can be used in routine care, aiming for better patient care in practice and, ultimately decreased extent of self-stigma, increased quality of life of patients, and decreased rates of depression, anxiety, and suicide ideation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Self-Stigma in Adults Living With Chronic Skin Disease: Development of the HautKompass Web-Based Program and Pilot Test of Its Usability, Acceptability, and Feasibility.
Traxler J, Stuhlmann CFZ, da Silva Burger N, Stierle C, et al · · 2025 · PMID 40402562 · DOI 10.2196/70290

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

NCT07443384 — Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus · not yet recruiting
NCT07385092 — Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery · NA · recruiting
NCT07009522 — Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART) · EARLY_PHASE1 · not yet recruiting
NCT07115394 — EEG Measurements to Capture DBS-induced Electric Potentials · recruiting
NCT06955884 — Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06324695 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf
Last refreshed: 8 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06324695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing